Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Allogene Therapeutics (ALLO) Operating Margin (2021 - 2024)

Allogene Therapeutics' Operating Margin history spans 4 years, with the latest figure at 315927.27% for Q1 2024.

  • For Q1 2024, Operating Margin rose 1437939.0% year-over-year to 315927.27%; the TTM value through Dec 2024 reached 1241813.64%, down 95929984.0%, while the annual FY2024 figure was 1241813.64%, 89682732.0% down from the prior year.
  • Operating Margin for Q1 2024 was 315927.27% at Allogene Therapeutics, up from 405280.95% in the prior quarter.
  • Across five years, Operating Margin topped out at 2.26% in Q4 2021 and bottomed at 2411525.0% in Q4 2022.
  • The 4-year median for Operating Margin is 205107.69% (2022), against an average of 376561.05%.
  • The largest annual shift saw Operating Margin crashed -241152726bps in 2022 before it skyrocketed 200624405bps in 2023.
  • A 4-year view of Operating Margin shows it stood at 2.26% in 2021, then tumbled by -106874311bps to 2411525.0% in 2022, then soared by 83bps to 405280.95% in 2023, then grew by 22bps to 315927.27% in 2024.
  • Per Business Quant, the three most recent readings for ALLO's Operating Margin are 315927.27% (Q1 2024), 405280.95% (Q4 2023), and 146453.49% (Q3 2023).